Skip to main content

Table 1 Clinical characteristics

From: Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention

Variables

Periprocedural Myocardial Injury

p value

No (n = 81)

Yes (n = 48)

Age (years)

68.7 ± 9.7

69.3 ± 10.1

0.75

Male, n (%)

69 (85.2)

38 (79.2)

0.38

Body mass index (kg/m2)

23.7 (21.9–26.7)

24.2 (22.4–25.9)

0.95

Current smoking, n (%)

15 (18.5)

13 (27.1)

0.25

Hypertension, n (%)

63 (77.8)

35 (72.9)

0.53

Diabetes mellitus, n (%)

39 (48.1)

20 (41.7)

0.48

Dyslipidemia, n (%)

62 (76.5)

35 (72.9)

0.65

Prior myocardial infarction, n (%)

20 (24.7)

18 (37.5)

0.10

eGFR (mL/min/1.73 m2)

69.0 (58.3–77.6)

65.1 (55.6–76.4)

0.37

Total cholesterol (mg/dL)

158 (139–180)

157 (125–186)

0.81

LDL cholesterol (mg/dL)

89 (74–106)

93 (70–113)

0.76

HDL cholesterol (mg/dL)

44.6 ± 10.3

41.0 ± 10.0

0.049

HDL2 cholesterol (mg/dL)

25.0 ± 6.8

23.5 ± 7.4

0.26

HDL3 cholesterol (mg/dL)

16.4 ± 2.9

15.1 ± 3.0

0.016

Triglycerides (mg/dL)

113 (85–163)

119 (93–156)

0.46

Hemoglobin A1c (%)

6.4 (5.9–6.9)

6.1 (5.7–6.7)

0.11

C-reactive protein (mg/L)

1.2 (0.5–3.4)

1.7 (0.8–4.3)

0.25

ACE-I or ARB, n (%)

54 (63.0)

28 (65.1)

0.34

Beta-blocker, n (%)

30 (37.0)

21 (48.8)

0.45

Calcium channel blocker, n (%)

28 (34.6)

19 (39.6)

0.57

Anti-diabetes drugs, n (%)

28 (34.6)

13 (27.1)

0.38

Statin, n (%)

67 (82.7)

40 (83.3)

0.93

Eicosapentaenoic acid, n (%)

6 (7.4)

5 (10.4)

0.55

Ezetimibe, n (%)

2 (2.5)

2 (4.2)

0.59

  1. Data are indicated as means ± SD or median (interquartile range) or number (percentages). eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, HDL high-density lipoprotein, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker